Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1Ovarian Neoplasms 1Metastatic Castrate- Resistant Prostate Cancer 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 29Carboplatin 25Topotecan 12Gemcitabine 11Cyclophosphamide 11Cisplatin 11Taxes 10Filgrastim 9sargramostim 8pembrolizumab 8Docetaxel 8Bevacizumab 8Peripheral Blood Stem Cell Transplantation 6liposomal doxorubicin 5Flow Cytometry 5Interleukin-12 Subunit p35 4Drug Therapy 4fludarabine phosphate 3fludarabine 3Sirolimus 3Nivolumab 3Melphalan 3Immunohistochemistry 3Immunoenzyme Techniques 3Granulocyte-Macrophage Colony-Stimulating Factor 3Fulvestrant 3Etoposide 3Chemotherapy, Adjuvant 3Capecitabine 31-dodecylpyridoxal 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Ovarian Epithelial × phenoxodiol × Clear all
NCT00303888 2018-01-17

Docetaxel With or Without Phenoxodiol in Treating Patients With Recurrent Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Yale University

Phase 1 Terminated
31 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡